Streetbeat News

AGTI

Agiliti Inc

Employees

1,868

agiliti is a company of 3,000 passionate equipment management experts who believe every interaction has the power to change a life. we’ve built a brand that’s dedicated to optimizing clinical outcomes while relentlessly improving economic outcomes for our customers.

Open

10.10

Mkt cap

1.4B

Volume

26M

High

10.10

P/E Ratio

-71.79

52-wk high

18.61

Low

10.05

Div yield

N/A

52-wk low

5.07

Agiliti, Inc. (NYSE:AGTI) shares surged after announcing it will be taken private by Thomas H. Lee Partners, L.P. for $10.00 per share in cash, valuing the company at approximately $2.5 billion. The deal, expected to close in the first half of 2024, provides immediate value and liquidity to shareholders, according to CEO Tom Leonard.

Portfolio Pulse from Erica Kollmann

February 26, 2024 | 5:25 pm

U.S. stocks traded mixed with the Dow and NASDAQ seeing slight gains, while the S&P 500 edged lower. Consumer discretionary shares rose, while utilities fell. Akili, Inc., Interactive Strength Inc., and Agiliti, Inc. saw significant stock increases due to positive business developments. Conversely, Aclarion, Inc., Intuitive Machines, Inc., and Venus Concept Inc. experienced notable declines. Crude oil prices increased by 1%, and U.S. new home sales rose by 1.5% in January.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 5:01 pm

Agiliti shares surged following the announcement that it will be taken private by THL Partners, indicating a significant corporate action that could affect its stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:49 pm

Agiliti Inc. (NYSE:AGTI) is set to go private in a deal with THL Partners, valuing the company at approximately $2.5 billion. Shareholders will receive $10 per share in cash, a significant premium over recent average prices. The deal, recommended by a special committee and approved by the board, is expected to close in the first half of 2024. Agiliti will not host a Q4 and full year 2023 earnings call but will file its annual report by March 15, 2024.

Portfolio Pulse from Happy Mohamed

February 26, 2024 | 1:10 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. ZyVersa Therapeutics, Agiliti, NeuBase Therapeutics, ImmunityBio, Monopar Therapeutics, and Altimmune were among the gainers with notable percentage increases in their stock prices. Conversely, ThermoGenesis Holdings, Aclarion, Telesis Bio, Venus Concept, Motus GI Holdings, and Cogent Biosciences experienced declines. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:06 pm

Keybanc analyst Brett Fishbin has initiated coverage on Agiliti (NYSE:AGTI) with a Sector Weight rating, indicating a neutral outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 11:48 am

Agiliti Inc.'s stock (AGTI) is trading higher following a Buy rating initiation and a $23 price target from Craig-Hallum.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:17 pm

Craig-Hallum analyst Matt Hewitt has initiated coverage on Agiliti (NYSE:AGTI) with a Buy rating and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:23 pm

Lamb Weston Holdings, Inc. (LW) reported better-than-expected quarterly earnings and sales, leading to a 4.7% rise in its stock price. Other stocks also moved higher, including Omega Therapeutics (OMGA) after a collaboration with Novo Nordisk, and Allstate Corporation (ALL) following an analyst upgrade. Various companies announced public offerings, collaborations, and financial forecasts, contributing to their stock movements.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 3:12 pm

Analysts have recently provided their opinions on Agiliti (NYSE:AGTI), with 1 bullish and 3 somewhat bearish ratings over the past 3 months. The average 12-month price target for AGTI is now $9.75, a significant decrease from the previous target of $14.75, indicating a potential downside of 33.9%. This change in target price reflects a more negative outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.